Phosphodiesterase type 5 inhibitors in pulmonary arter

Advances in Therapy 26, 813-825 DOI: 10.1007/s12325-009-0064-z

Citation Report

#	Article	IF	CITATIONS
1	Pulmonary-Respiratory Medicine. JAMA - Journal of the American Medical Association, 2001, 285, 943.	7.4	0
4	Phosphodiesterase inhibition with tadalafil provides longer and sustained protection of stem cells. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1395-H1404.	3.2	52
5	Novel therapeutic strategies targeting vascular endothelium in essential hypertension. Expert Opinion on Investigational Drugs, 2010, 19, 1395-1412.	4.1	12
6	Tadalafil. Drugs, 2010, 70, 479-488.	10.9	17
7	Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opinion on Investigational Drugs, 2010, 19, 1427-1437.	4.1	72
10	Response to Inhaled Nitric Oxide Predicts Survival in Patients With Pulmonary Hypertension. Journal of Cardiac Failure, 2011, 17, 265-271.	1.7	19
11	RAF-isotype switching: from B to C through PDE. Nature Structural and Molecular Biology, 2011, 18, 517-518.	8.2	1
12	High-performance liquid chromatographic method with amperometric detection employing boron-doped diamond electrode for the determination of sildenafil, vardenafil and their main metabolites in plasma. Journal of Chromatography A, 2011, 1218, 7996-8001.	3.7	23
13	Effect of tadalafil in chronic renal failure rabbits: relevance to erectile dysfunction. Journal of Zhejiang University: Science B, 2011, 12, 455-459.	2.8	0
14	Viagra deafness—Sensorineural hearing loss and phosphodiesteraseâ€5 inhibitors. Laryngoscope, 2011, 121, 1049-1054.	2.0	42
15	A fully validated method for the determination of vardenafil in blood using gas chromatography/mass spectrometry. Journal of Mass Spectrometry, 2011, 46, 71-76.	1.6	9
16	Sildenafil and FDP-Sr attenuate diabetic cardiomyopathy by suppressing abnormal expression of myocardial CASQ2, FKBP12.6, and SERCA2a in rats. Acta Pharmacologica Sinica, 2011, 32, 441-448.	6.1	11
17	New insights into hypertension-associated erectile dysfunction. Current Opinion in Nephrology and Hypertension, 2012, 21, 163-170.	2.0	91
18	Sildenafil Plasma Concentrations in Two HIV Patients with Pulmonary Hypertension Treated with Ritonavir-Boosted Protease Inhibitors. Current HIV Research, 2012, 10, 162-164.	0.5	22
20	Acute Effects of Vardenafil on Pulmonary Artery Responsiveness in Pulmonary Hypertension. Scientific World Journal, The, 2012, 2012, 1-6.	2.1	12
21	Vardenafil Ameliorates Calcium Mobilization in Pulmonary Artery Smooth Muscle Cells from Hypoxic Pulmonary Hypertensive Mice. Archives of Medical Research, 2012, 43, 265-273.	3.3	4
23	Age-Related Changes in Speed and Mechanism of Adult Skeletal Muscle Stem Cell Migration. Stem Cells, 2012, 30, 1182-1195.	3.2	68
24	Pulmonary veno-occlusive disease: a misnomer?. Pediatric Radiology, 2012, 42, 647-652.	2.0	7

ATION REPO

	CITATION N		
#	Article	IF	CITATIONS
25	Phosphodiesterase 5 inhibitors in vascular systemic disorders. Joint Bone Spine, 2012, 79, 338-340.	1.6	3
26	Trace determination of vardenafil hydrochloride in commercial formulation and human serum by adsorptive anodic stripping voltammetry at a carbon paste electrode. Journal of Solid State Electrochemistry, 2013, 17, 1891-1902.	2.5	17
27	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1193-1205.	3.3	22
28	Sildenafil citrate monohydrate–cyclodextrin nanosuspension complexes for use in metered-dose inhalers. International Journal of Pharmaceutics, 2013, 455, 248-258.	5.2	29
29	Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases, 2013, 8, 97.	2.7	226
30	Pulmonary Hypertension: Use of Oral Drugs in Patients with Renal Insufficiency. Clinical Drug Investigation, 2013, 33, 65-69.	2.2	0
31	The potent relaxant effect of resveratrol in rat corpus cavernosum and its underlying mechanisms. International Journal of Impotence Research, 2013, 25, 188-193.	1.8	15
32	Inhibition of phosphodiesterase-5 rescues age-related impairment of synaptic plasticity and memory. Behavioural Brain Research, 2013, 240, 11-20.	2.2	61
33	Assessment of the Endothelial Functions in Monocrotaline-induced Pulmonary Hypertension. Clinical and Experimental Hypertension, 2013, 35, 220-227.	1.3	8
34	Combination of Erythropoietin and Sildenafil Can Effectively Attenuate Hypoxiaâ€Induced Pulmonary Hypertension in Mice. Pulmonary Circulation, 2013, 3, 898-907.	1.7	6
35	Reactive oxygen species as therapeutic targets in pulmonary hypertension. Therapeutic Advances in Respiratory Disease, 2013, 7, 175-200.	2.6	48
36	Intravenous Sildenafil in Right Ventricular Dysfunction with Pulmonary Hypertension following a Heart Transplant. Heart International, 2014, 9, HEART.2014.1249.	1.4	4
37	Increased pulmonary vascular expression of Krüppel-like factor 5 and activated survivin in experimental congenital diaphragmatic hernia. Pediatric Surgery International, 2014, 30, 1191-1197.	1.4	7
38	Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension. Journal of Translational Medicine, 2014, 12, 250.	4.4	31
39	An evaluation of vardenafil as a calcium channel blocker in pulmonary artery in rats. Indian Journal of Pharmacology, 2014, 46, 185.	0.7	6
40	Changes in the pharmacokinetic of sildenafil citrate in rats with Streptozotocin-induced diabetic nephropathy. Journal of Diabetes and Metabolic Disorders, 2014, 13, 8.	1.9	12
41	Targeted therapies in pulmonary arterial hypertension. , 2014, 141, 172-191.		171
42	A review of phosphodiesterase type 5 inhibitors. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2014, 56, 96-101.	0.6	7

#	Article	IF	CITATIONS
43	PDE5 inhibitor sildenafil in the treatment of heart failure: A meta-analysis of randomized controlled trials. International Journal of Cardiology, 2014, 172, 581-587.	1.7	40
44	Antenatal maternally-administered phosphodiesterase type 5 inhibitors normalize eNOS expression in the fetal lamb model of congenital diaphragmatic hernia. Journal of Pediatric Surgery, 2014, 49, 39-45.	1.6	22
45	Evaluation of sildenafil pressurized metered dose inhalers as a vasodilator in umbilical blood vessels of chicken egg embryos. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 90-97.	4.3	15
46	Increased pulmonary vascular expression of receptor for advanced glycation end products (RAGE) in experimental congenital diaphragmatic hernia. Journal of Pediatric Surgery, 2015, 50, 746-749.	1.6	6
47	Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5. Bioorganic and Medicinal Chemistry, 2015, 23, 2121-2128.	3.0	22
48	New pharmacotherapy options for pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2015, 16, 2113-2131.	1.8	20
50	Histological evaluation of the rat dental pulp after indirect capping with sildenafil or L-NAME incorporated into a bioadhesive thermoresponsive system. Acta Scientiarum - Health Sciences, 2016, 38, 95.	0.2	3
51	Pharmacological Profile of CPD-1116, an Inhibitor of Phosphodiesterase 4. Biological and Pharmaceutical Bulletin, 2016, 39, 689-698.	1.4	9
53	Pharmacological treatment of HIV-associated pulmonary hypertension. Expert Review of Clinical Pharmacology, 2016, 9, 715-725.	3.1	5
54	Emerging targets for addiction neuropharmacology. Progress in Brain Research, 2016, 224, 251-284.	1.4	11
55	Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension. Respiratory Medicine Case Reports, 2017, 20, 45-47.	0.4	6
56	Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities. Therapeutic Advances in Chronic Disease, 2017, 8, 47-64.	2.5	26
57	Comparing the Efficacy of Tadalafil Versus Placebo on Pulmonary Artery Systolic Pressure and Right Ventricular Function in Patients with Beta-Thalassaemia Intermedia. Heart Lung and Circulation, 2017, 26, 677-683.	0.4	8
58	Sildenafil improves blood perfusion in steroid-induced avascular necrosis of femoral head in rabbits via a protein kinase G-dependent mechanism. Acta Orthopaedica Et Traumatologica Turcica, 2017, 51, 398-403.	0.8	15
59	Effects of Sildenafil and Tadalafil on Edema and Reactive Oxygen Species Production in an Experimental Model of Lung Ischemia-Reperfusion Injury. Transplantation Proceedings, 2017, 49, 1461-1466.	0.6	13
60	Reynolds Syndrome: a rare rheumatologic disease that internists should have in mind. Case report. Case Reports, 2017, 3, .	0.0	0
61	Pre-operative Evaluation of Patients with Pulmonary Hypertension. Current Anesthesiology Reports, 2018, 8, 44-51.	2.0	0
62	3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats. European Journal of Pharmacology, 2018, 829, 102-111.	3.5	14

CITATION REPORT

#	Article	IF	CITATIONS
63	Pharmacokinetics of singleâ€dose sildenafil administered orally in clinically healthy dogs: Effect of feeding and dose proportionality. Journal of Veterinary Pharmacology and Therapeutics, 2018, 41, 457-462.	1.3	11
64	Analysis of short-term treatment with the phosphodiesterase type 5 inhibitor tadalafil on long bone development in young rats. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E446-E453.	3.5	6
65	Optimization of Chromeno[2,3- <i>c</i>]pyrrol-9(2 <i>H</i>)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure–Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension. Journal of Medicinal Chemistry, 2018, 61, 8468-8473.	6.4	21
66	Genome-Wide Association Analysis of Single-Breath D <scp>l</scp> _{CO} . American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 523-531.	2.9	8
67	Hunteria umbellata seed extract administration modulates activities of phosphodiesterase-5 and purinergic enzymes relevant to erection in normal male rats. Oriental Pharmacy and Experimental Medicine, 2019, 19, 167-175.	1.2	2
68	Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and metaâ€analysis. Acta Ophthalmologica, 2020, 98, 22-31.	1.1	7
69	Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy. Bioorganic Chemistry, 2020, 105, 104352.	4.1	10
70	Pulmonary arterial hypertension and heart failure with preserved ejection fraction: are they so discordant?. Cardiovascular Diagnosis and Therapy, 2020, 10, 534-545.	1.7	5
71	Emerging antenatal therapies for congenital diaphragmatic hernia-induced pulmonary hypertension in preclinical models. Pediatric Research, 2021, 89, 1641-1649.	2.3	5
72	Magnesium lithospermate B ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition and its potential targets. Biomedicine and Pharmacotherapy, 2020, 130, 110560.	5.6	6
73	Relaxation Effect of Patchouli Alcohol in Rat Corpus Cavernous and Its Underlying Mechanisms. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-11.	1.2	2
74	Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension. Frontiers in Medicine, 2020, 7, 616720.	2.6	6
75	Idiopathic Pulmonary Arterial Hypertension in the Pediatric Age Group. , 2021, , 1-24.		0
76	Pulmonary arterial hypertension specific therapy: The old and the new. , 2020, 214, 107576.		38
77	The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets. Current Medicinal Chemistry, 2020, 27, 7168-7188.	2.4	27
78	Hetero-Tricyclic Lead Scaffold as Novel PDE5A Inhibitor for Antihypertensive Activity: In Silico Docking Studies. Current Computer-Aided Drug Design, 2019, 15, 318-333.	1.2	3
79	Current and emerging therapeutic approaches to pulmonary hypertension. Reviews in Cardiovascular Medicine, 2020, 21, 163.	1.4	51
80	Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. Cardiovascular Drugs and Therapy, 2023, 37, 793-806.	2.6	10

CITATION REPORT

CITATION REPORT

#	Article	IF	CITATIONS
81	Acute Unilateral Vestibular Weakness Following Sildenafil Ingestion. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2012, 55, 513.	0.2	0
82	A Novel Adenosine A2a Receptor Agonist Attenuates the Progression of Monocrotaline-induced Pulmonary Hypertension in Rats. Journal of Pulmonary & Respiratory Medicine, 0, , .	0.1	0
83	Osthole alleviates pulmonary vascular remodeling by modulating microRNA-22–3p mediated lipid metabolic reprogramming. Phytomedicine, 2022, 96, 153840.	5.3	4
84	Intravenous sildenafil in right ventricular dysfunction with pulmonary hypertension following a heart transplant. Heart International, 2014, 9, 22-5.	1.4	1
85	Beneficial Extracardiac Effects of Cardiovascular Medications. Current Cardiology Reviews, 2022, 18, .	1.5	3
86	A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities. Blood Research, 2021, 56, 229-242.	1.3	19
87	PDE1 inhibitors: a review of the recent patent literature (2008-present). Expert Opinion on Therapeutic Patents, 2022, 32, 423-439.	5.0	5
88	The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future. , 2022, 239, 108192.		7
89	Secular Trends in Systemic Sclerosis Mortality in the United States from 1981 to 2020. International Journal of Environmental Research and Public Health, 2022, 19, 15088.	2.6	0
90	A pilot study to explore the effect of udenafil on cerebral hemodynamics in older adults. Annals of Clinical and Translational Neurology, 2023, 10, 933-943.	3.7	1
91	Repurposing Drugs: A New Paradigm and Hopes for Life-threatening Diseases. , 2023, , 1-24.		0
92	PDE5 inhibitors and gastric mucosa: implications for the management of peptic ulcer disease. Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396, 2261-2267.	3.0	1
93	A Novel Electrochemical Sensor for Determination of Sildenafil Citrate (Viagra) in Pure Form and in Biological and Pharmaceutical Formulations. International Journal of Electrochemical Science, 2012, 7, 13008-13019.	1.3	8
94	Pulmonary Arterial Hypertension in the Elderly: Peculiar Features and Challenges for a Proper Phenotyping Approach. Journal of Cardiovascular Development and Disease, 2023, 10, 401.	1.6	1
95	PDE5 inhibitors: breaking new grounds in the treatment of COVID-19. Drug Metabolism and Personalized Therapy, 2023, .	0.6	4
96	PDE5 inhibitors: breaking new grounds in the treatment of COVID-19. Drug Metabolism and Personalized Therapy, 2024, 38, 295-307.	0.6	0